Experience

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

Davis Polk is advising Emerson Electric Co. on its $1.6 billion acquisition of Open Systems International, Inc. Emerson, headquartered in St. Louis, Missouri, is a global technology and…

Davis Polk advised the joint book-running managers in connection with an SEC-registered offering by Honeywell International Inc. of $2.5 billion aggregate principal amount of its 0.483…

Davis Polk advised Freeline Therapeutics Holdings plc on its $158.8 million initial public offering of 8,823,529 American depositary shares representing 8,823,529 ordinary shares, which…

Davis Polk is advising Clarivate Plc on its approximately $6.8 billion combination with CPA Global. In the all-stock transaction, CPA Global shareholders will receive approximately 218…

Davis Polk advised Centogene N.V. on its $49 million follow-on public offering of 3,500,000 of its common shares, consisting of 2,000,000 common shares offered by Centogene and 1,500,000…

Davis Polk advised BRP Group, Inc. on its $175.2 million follow-on offering of 13,225,000 shares of Class A common stock, which includes 1,725,000 shares from the full exercise of the…

Davis Polk advised Uniti Group Inc., as issuer, in connection with a new SEC-registered at-the-market offering program by Uniti under which Uniti may issue and sell shares of its common…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by Applied Therapeutics, Inc. of shares of its common stock for up to a maximum offering…